BMS Sees Another Setback As Milvexian Fails Phase III Test

Anticoagulant Once Projected To Be A $5bn Product

 
• By Mandy Jackson
  
A Phase III trial in acute coronary syndrome has been stopped, but atrial fibrillation is a larger market for milvexian (Shutterstock)

More from Scrip

More from Clinical Trials